We are analyzing https://link.springer.com/article/10.1007/s13277-013-1547-8.

Title:
Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG | Tumor Biology
Description:
We conducted a retrospective study to determine the prognostic significance of age, gender, associated carcinoma in situ, stage, number of tumors, and tumor size for patients with high-risk non-muscle-invasive bladder tumors treated with bacillus Calmette-Guérin (BCG). Data were evaluated on 144 high-risk patients with non-muscle-invasive bladder cancer treated with BCG immunotherapy after the initial treatment with transurethral resection. According to their response to BCG, patients were divided into groups, and the differences in factors, associated with recurrence and progression, were evaluated. Patients were categorized into two groups: group A, complete responders without recurrence and without progression, and group B, patients with recurrence and with progression. Furthermore, group B was divided into two subgroups: group B1, patients with recurrence, and group B2, patients with progression. Univariate analysis of group B showed that only tumor size of >3 cm diameter (hazard ratio (HR) 11.99; 95 % confidence interval (CI) range 5.69–25.3; p < 0.001) is associated with recurrence. After multivariate analysis, the same factor appeared to be prognostic for recurrence as well. In addition, group B2 was statistically correlated with group B1. Univariate analysis proved that tumor stage (Ta or T1) is the unique factor associated with progression (HR 6.4; 95 % CI 1.29–31.9; p = 0.02). Tumor stage seems to be associated with disease
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Social Networks
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

bladder, article, cancer, patients, google, scholar, progression, pubmed, tumor, recurrence, stage, urol, bcg, treated, bacillus, group, cas, highrisk, nonmuscleinvasive, carcinoma, calmetteguérin, analysis, size, superficial, privacy, cookies, content, zachos, prognostic, tumors, access, eur, data, publish, research, search, michael, intravesical, urology, dose, author, department, greece, information, log, journal, adjuvant, december, ioannis, tzortzis,

Topics {✒️}

muscle-invasive bladder cancer muscle-invasive urothelial carcinoma month download article/chapter intravesical bacille calmette-guérin conventional rotisserie method bacillus calmette-guérin treatment superficial bladder cancer bacillus calmette-guérin prospective randomized trial low-dose bcg long-term efficacy results full article pdf related subjects bcg intravesical immunotherapy bacillus calmette-guerin eortc risk tables privacy choices/manage cookies stage correlate independently long-term follow tumor size early cystectomy improve article zachos standard 81 mg dose adjuvant bcg immunotherapy stage t1 european economic area muscularis mucosae invasion �agios andreas’ hospital 1007/s13277-013-1547-8 keywords 144 high-risk patients high-risk patients tumor stage muscle invasion conditions privacy policy ten-year follow minimum 10-year followup accepting optional cookies cueto scoring model greece athanasios retrospective study article log univariate analysis proved main content log bcg-treated ioannis zachos journal finder publish author correspondence check access instant access article cite

Questions {❓}

Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
         description:We conducted a retrospective study to determine the prognostic significance of age, gender, associated carcinoma in situ, stage, number of tumors, and tumor size for patients with high-risk non-muscle-invasive bladder tumors treated with bacillus Calmette-Guérin (BCG). Data were evaluated on 144 high-risk patients with non-muscle-invasive bladder cancer treated with BCG immunotherapy after the initial treatment with transurethral resection. According to their response to BCG, patients were divided into groups, and the differences in factors, associated with recurrence and progression, were evaluated. Patients were categorized into two groups: group A, complete responders without recurrence and without progression, and group B, patients with recurrence and with progression. Furthermore, group B was divided into two subgroups: group B1, patients with recurrence, and group B2, patients with progression. Univariate analysis of group B showed that only tumor size of >3 cm diameter (hazard ratio (HR) 11.99; 95 % confidence interval (CI) range 5.69–25.3; p < 0.001) is associated with recurrence. After multivariate analysis, the same factor appeared to be prognostic for recurrence as well. In addition, group B2 was statistically correlated with group B1. Univariate analysis proved that tumor stage (Ta or T1) is the unique factor associated with progression (HR 6.4; 95 % CI 1.29–31.9; p = 0.02). Tumor stage seems to be associated with disease's progression after the multivariate analysis too. Tumor size and stage may serve as prognostic factors, because of its independent correlation with recurrence and progression for patients with high-risk non-muscle-invasive bladder tumors treated with BCG.
         datePublished:2013-12-28T00:00:00Z
         dateModified:2013-12-28T00:00:00Z
         pageStart:4185
         pageEnd:4189
         sameAs:https://doi.org/10.1007/s13277-013-1547-8
         keywords:
            Non-muscle invasive bladder cancer
            Tumor size
            Tumor stage
            BCG
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-013-1547-8/MediaObjects/13277_2013_1547_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-013-1547-8/MediaObjects/13277_2013_1547_Fig2_HTML.gif
         isPartOf:
            name:Tumor Biology
            issn:
               1423-0380
               1010-4283
            volumeNumber:35
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ioannis Zachos
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Vasileios Tzortzis
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lampros Mitrakas
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael Samarinas
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anastasios Karatzas
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stavros Gravas
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gerasimos P. Vandoros
               affiliation:
                     name:‘Agios Andreas’ Hospital
                     address:
                        name:Department of Pathology, ‘Agios Andreas’ Hospital, Patras, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael D. Melekos
               affiliation:
                     name:University of Thessalia
                     address:
                        name:Department of Urology, University of Thessalia, Larissa, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Athanasios G. Papavassiliou
               affiliation:
                     name:University of Athens
                     address:
                        name:Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG
      description:We conducted a retrospective study to determine the prognostic significance of age, gender, associated carcinoma in situ, stage, number of tumors, and tumor size for patients with high-risk non-muscle-invasive bladder tumors treated with bacillus Calmette-Guérin (BCG). Data were evaluated on 144 high-risk patients with non-muscle-invasive bladder cancer treated with BCG immunotherapy after the initial treatment with transurethral resection. According to their response to BCG, patients were divided into groups, and the differences in factors, associated with recurrence and progression, were evaluated. Patients were categorized into two groups: group A, complete responders without recurrence and without progression, and group B, patients with recurrence and with progression. Furthermore, group B was divided into two subgroups: group B1, patients with recurrence, and group B2, patients with progression. Univariate analysis of group B showed that only tumor size of >3 cm diameter (hazard ratio (HR) 11.99; 95 % confidence interval (CI) range 5.69–25.3; p < 0.001) is associated with recurrence. After multivariate analysis, the same factor appeared to be prognostic for recurrence as well. In addition, group B2 was statistically correlated with group B1. Univariate analysis proved that tumor stage (Ta or T1) is the unique factor associated with progression (HR 6.4; 95 % CI 1.29–31.9; p = 0.02). Tumor stage seems to be associated with disease's progression after the multivariate analysis too. Tumor size and stage may serve as prognostic factors, because of its independent correlation with recurrence and progression for patients with high-risk non-muscle-invasive bladder tumors treated with BCG.
      datePublished:2013-12-28T00:00:00Z
      dateModified:2013-12-28T00:00:00Z
      pageStart:4185
      pageEnd:4189
      sameAs:https://doi.org/10.1007/s13277-013-1547-8
      keywords:
         Non-muscle invasive bladder cancer
         Tumor size
         Tumor stage
         BCG
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-013-1547-8/MediaObjects/13277_2013_1547_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13277-013-1547-8/MediaObjects/13277_2013_1547_Fig2_HTML.gif
      isPartOf:
         name:Tumor Biology
         issn:
            1423-0380
            1010-4283
         volumeNumber:35
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ioannis Zachos
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Vasileios Tzortzis
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lampros Mitrakas
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael Samarinas
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anastasios Karatzas
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stavros Gravas
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gerasimos P. Vandoros
            affiliation:
                  name:‘Agios Andreas’ Hospital
                  address:
                     name:Department of Pathology, ‘Agios Andreas’ Hospital, Patras, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael D. Melekos
            affiliation:
                  name:University of Thessalia
                  address:
                     name:Department of Urology, University of Thessalia, Larissa, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Athanasios G. Papavassiliou
            affiliation:
                  name:University of Athens
                  address:
                     name:Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Tumor Biology
      issn:
         1423-0380
         1010-4283
      volumeNumber:35
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:‘Agios Andreas’ Hospital
      address:
         name:Department of Pathology, ‘Agios Andreas’ Hospital, Patras, Greece
         type:PostalAddress
      name:University of Thessalia
      address:
         name:Department of Urology, University of Thessalia, Larissa, Greece
         type:PostalAddress
      name:University of Athens
      address:
         name:Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ioannis Zachos
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Vasileios Tzortzis
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Lampros Mitrakas
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Michael Samarinas
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Anastasios Karatzas
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Stavros Gravas
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Gerasimos P. Vandoros
      affiliation:
            name:‘Agios Andreas’ Hospital
            address:
               name:Department of Pathology, ‘Agios Andreas’ Hospital, Patras, Greece
               type:PostalAddress
            type:Organization
      name:Michael D. Melekos
      affiliation:
            name:University of Thessalia
            address:
               name:Department of Urology, University of Thessalia, Larissa, Greece
               type:PostalAddress
            type:Organization
      name:Athanasios G. Papavassiliou
      affiliation:
            name:University of Athens
            address:
               name:Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Pathology, ‘Agios Andreas’ Hospital, Patras, Greece
      name:Department of Urology, University of Thessalia, Larissa, Greece
      name:Department of Biological Chemistry, Medical School, University of Athens, Athens, Greece
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(99)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

3.78s.

LINK . SPRINGER . COM {}